Aquestive Therapeutics (AQST) Operating Income: 2017-2025
Historic Operating Income for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$11.5 million.
- Aquestive Therapeutics' Operating Income fell 38.47% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 164.37%. This contributed to the annual value of -$30.8 million for FY2024, which is 103.75% down from last year.
- Latest data reveals that Aquestive Therapeutics reported Operating Income of -$11.5 million as of Q3 2025, which was down 0.98% from -$11.4 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Operating Income high stood at $55,000 for Q2 2024, and its period low was -$19.4 million during Q1 2025.
- In the last 3 years, Aquestive Therapeutics' Operating Income had a median value of -$8.3 million in 2024 and averaged -$8.0 million.
- Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 101.31% in 2024, then tumbled by 20,769.09% in 2025.
- Quarterly analysis of 5 years shows Aquestive Therapeutics' Operating Income stood at -$11.7 million in 2021, then grew by 8.19% to -$10.7 million in 2022, then soared by 63.49% to -$3.9 million in 2023, then plummeted by 247.20% to -$13.6 million in 2024, then crashed by 38.47% to -$11.5 million in 2025.
- Its Operating Income was -$11.5 million in Q3 2025, compared to -$11.4 million in Q2 2025 and -$19.4 million in Q1 2025.